You just read:

Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma

News provided by

AEGERA THERAPEUTICS INC.

Jan 26, 2010, 08:30 ET